[Relationship between auditory disability and auditory threshold in acute acoustic trauma: pilot study]. / Rapporto tra disability uditiva e soglia audiometrica nel trauma acustico cronico: studio pilota.

The aim of this study was to determine the relationship existing between auditory disability, according to WHO 1980, and pure tone audiometry threshold in noise induced hearing loss. Disability was evaluated on the basis of a questionnaire submitted to 286 subjects with acoustic trauma. Answers obtained were considered reliable on the basis of statistical analysis. Results showed that subjects with disability have an higher pure tone threshold than subjects without auditory disability. However it appears difficult to determine a precise threshold level ever which auditory disability may be considered present. The Authors suggest that this limit could be determined on the basis of pure tone threshold at the 10th centile of the group of subjects with disability or at the 90th centile of subjects without disability.

Treatment of advanced non-small cell lung cancer (NSCLC): the "Umbria" cooperative study.

One hundred fifty-six patients with metastatic or locally advanced non-small cell lung cancer (NSCLC) were randomized to 3-week cycles of treatment with either: (A) cisplatin (120 mg/m2 on day 1); (B) cisplatin (120 mg/m2 on day 1) plus etoposide (VP-16) (100 mg/m2 on days 1-3; and (C) the cisplatin plus etoposide (VP-16) regimen plus mitomycin C (10 mg/m2 on days 1, 21, and 42; then every 6 weeks for a maximum dose of 100 mg). The overall objective response rates for the combination regimens (30% with two drugs and 26% with three drugs) were superior to that obtained with one drug (4%). Likewise, the median duration of survival with the combination therapy arms (8 to 9 months) was superior to that obtained with the single agent (5 months). Both performance status and limited disease were correlated with response in all groups, and with survival in the combined chemotherapy arms. The dose-limiting toxicity was myelosuppression, especially for the group receiving the three-drug regimen. In summary, combination chemotherapy using cisplatin and etoposide (VP-16) appears to be the most active and safest regimen in NSCLC.